Key result
The provided abstract is truncated and does not report any quantitative results regarding the efficacy of pitavastatin on lipid and glucose metabolism in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Type 2 diabetes is one of the risk factors for macrovascular disease. Treatment of hypercholesterolemia is important in patients with type 2 diabetes to prevent macrovascular disease. The 3-hydroxy-3-methyl glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are key drugs to lower the cholesterol level not only in nondiabetic patients but also in patients with type 2 diabetes. However, some statins might worsen glycemic control (1) whereas some of them might be neutral (2) or improve glycemic control (3), and their effects on glucose metabolism are controversial. Pitavastatin, an HMG-CoA reductase inhibitor, has been available in Japan since 2003 (4) and the Republic of Korea since 2005, and its effect on glucose metabolism in diabetic patients …
Kawai et al. (2005) studied Type 2 diabetes. Pitavastatin was evaluated on Lipid and glucose metabolism. The provided abstract is truncated and does not report any quantitative results regarding the efficacy of pitavastatin on lipid and glucose metabolism in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: